The $1 trillion GLP-1 revolution with Rod Wong

What It Covers

Rod Wong, founder and CIO of RTW Investments, explains how GLP-1 drugs for obesity represent the first healthcare innovation to create over $1 trillion in value. He covers current market dynamics, future drug development waves through 2030, cost effectiveness analysis, manufacturing constraints, and investment opportunities in both public and private companies.

Key Questions Answered

• •Market Size and Timeline: GLP-1 drugs currently generate $40 billion annually with two-thirds from diabetes treatment. Consensus projects growth to $125 billion as the market triples. The duopoly between Eli Lilly's tirzepatide products and Novo's semaglutide products continues through 2025, with first oral medications arriving in 2026-2027 and more potent injectables by 2028-2030, creating multiple investment waves.
• •Health Outcomes Data: Clinical outcome studies demonstrate 20-30% improvements across multiple conditions including heart failure, kidney disease, osteoarthritis, fatty liver, and sleep apnea. Obesity affects over 100 million Americans and links directly to three of the top ten causes of death: cardiovascular disease, stroke, and diabetes. The drugs work through weight loss plus additional mechanisms like reducing inflammation.
• •Cost Effectiveness Analysis: US net prices currently range from $4,000-$5,000 annually with insurance coverage. ICER analysis shows cost effectiveness at $7,500-$10,000 per year despite bias against innovation. Broad GLP-1 adoption could reduce food spending by $50 billion annually. Consumer willingness to pay ranges from $500 to $4,000 yearly depending on income level, with forced generic substitution after patent expiry not factored into analyses.
• •Patient Adherence Challenge: Half of patients discontinue GLP-1 medications within six months due to side effects including nausea, vomiting, and diarrhea, or after achieving desired weight loss. This creates opportunities for differentiated products with better tolerability profiles, alternative delivery mechanisms like oral formulations, or novel mechanisms like amylin that provide satiety without reducing appetite, allowing multiple products to succeed simultaneously.
• •Investment Opportunity Structure: Only 10 publicly traded biotech companies currently focus on obesity despite it being the largest pharmaceutical opportunity in history. This number should expand to 30 companies, creating significant private investment opportunities. RTW expects 30% industry cash flow increase from GLP-1s, adding $50 billion for acquisitions and R&D. Half of major pharma companies pursue obesity through licensing or acquisition rather than internal development.